Fulvestrant + abemaciclib (HR+/HER2- metastatic 2L post-AI)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-FULVESTRANT DRUG-ABEMACICLIB |
|---|
| ID | REG-FULVESTRANT-ABEMACICLIB |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Notes
MONARCH-2: PFS + OS benefit post-AI failure. Diarrhea management is the dominant clinical workflow burden — patient-counseling and immediate access to loperamide critical.
Used By
No reverse references found in the YAML corpus.